The company said its decision was not based on any emerging safety concerns from the phase 3 clinical trials with fulranumab. Janssen Pharmaceuticals is terminating its licensing deal
The companies did not disclose the value of the deal, even though Dr. Reddy’s said it will pay Eisai milestone payments related to securing marketing approval and achieving
Opdivo is currently approved to treat various types of melanoma, lung cancer and kidney cancer. The data supporting the type II variation application was generated in the phase
The companies said the request was expected as part of the regulatory process and they will continue to work with the FTC in connection with the review. Pfizer
The US District Court for Southern Florida ruled that Allergan’s subsidiaries Watson Pharma and Watson Laboratories had infringed on two claims of the Lialda drug patent. Shire senior
The agency issued a complete response letter (CRL) to Lundbeck and its Japanese partner Takeda Pharmaceutical declining to expand the drug’s approval to treat various aspects of cognitive
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of Nuplazid outweighed the risks of treatment. The FDA
Ubenimex is an oral, small-molecule, dual-inhibitor of aminopeptidase and leukotriene A4 hydrolase (LTA4H), the enzyme which catalyzes the committed step in the formation of the pro-inflammatory mediator, LTB4.
Bendeka (bendamustine hydrochloride injection, or bendamustine HCI) is a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. It was approved in December last year
The research collaboration will integrate Forge’s expertise in metalloenzymes with Active Motif’s knowledge in epigenetics and related technologies. Under the alliance, the companies intend to validate emerging epigenetic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.